ASCLF News and Press, Ascletis Pharma Inc.

2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...

2024-04-09 10:03:48 ET More on Madrigal Pharmaceuticals Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly I...

2024-03-18 17:45:43 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva resumes Phase 3 study for NASH drug, stock up 6% Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alphaȁ...

2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...

2024-01-28 09:05:00 ET Summary ArriVent BioPharma (NSDQ: AVBP), a Philadelphia in-licensing company, priced its upsized NASDAQ IPO at $18 per share, raising $175 million. A siRNA therapy developed by Shanghai Refreshgene Therapeutics enables children with genetic deafness to hear....

2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...

Summary HutchMed out-licensed global rights (ex-China) for a colorectal cancer therapy, fruquintinib, to Takeda Pharmaceutical in a deal worth up to $1.13 billion, including $400 million upfront. Guangzhou Akeso was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatm...

Ascletis Pharma ( OTCPK:ASCLF ) subsidiary Ascletis Pharmaceuticals enters a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical, a subsidiary of Simcere Pharmaceutical Group. Ascletis currently owns the only authorized ritonavir oral tablet in China, wh...

Summary Chengdu WestGene Biopharma completed a $21 million Series A Round to advance its portfolio of nearly 20 mRNA candidates, including its lead COVID-19 vaccine, which is in IND stage. Suzhou GenAssist Therapeutics raised “millions of dollars” in an A round to support ...

Ascletis Pharma ( OTCPK:ASCLF ) said China's National Medical Products Administration (NMPA) approved its investigational new drug (IND) application to start a trial of oral drug ASC11 for COVID-19. The goal of the phase 1 trial, which is expected to be completed within Q1 2023, ...